Literature DB >> 11054660

IGFBP-3 prolongs the p53 response and enhances apoptosis following UV irradiation.

A D Hollowood1, T Lai, C M Perks, P V Newcomb, D Alderson, J M Holly.   

Abstract

Neoplastic transformation is characterised by an imbalance in favour of cell growth over programmed cell death (apoptosis). The tumour-suppressor gene p53, responsible for maintaining cell-cycle control, is mutated in the majority of human cancers. Loss of function of the target genes of p53 are therefore important in tumourigenesis. One such target gene is the insulin-like growth factor binding protein-3 (IGFBP-3), an extracellular protein responsible for the carriage of IGF-I but which can act independently of IGF-I, inhibiting cell growth and enhancing apoptosis. Using the KYSE 190 oesophageal carcinoma cell line, we have demonstrated that IGFBP-3 alone has no effect on cell growth or cell survival. However, it significantly enhanced apoptosis, with a 67% increase in the pre-G1 peak on flow cytometry following UV irradiation. The increase in p53 was enhanced and prolonged when cells are stressed in the presence of IGFBP-3. These data suggest an autocrine/paracrine feedback loop exists between IGFBP-3 and p53, which may provide the social control necessary to maintain normal tissue homeostasis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11054660

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  22 in total

1.  Low expression of IGFBP-3 predicts poor prognosis in patients with esophageal squamous cell carcinoma.

Authors:  Lei Zhao; Li-Ru He; Rui Zhang; Mu-Yan Cai; Yi-Ji Liao; Dong Qian; Mian Xi; Yi-Xin Zeng; Dan Xie; Meng-Zhong Liu
Journal:  Med Oncol       Date:  2011-12-14       Impact factor: 3.064

Review 2.  Insulin like growth factor-1 and insulin-like growth factor binding proteins: their possible roles in both maintaining normal retinal vascular function and in promoting retinal pathology.

Authors:  Lynn C Shaw; Maria B Grant
Journal:  Rev Endocr Metab Disord       Date:  2004-08       Impact factor: 6.514

Review 3.  Dietary factors and the risks of oesophageal adenocarcinoma and Barrett's oesophagus.

Authors:  Ai Kubo; Douglas A Corley; Christopher D Jensen; Rubinder Kaur
Journal:  Nutr Res Rev       Date:  2010-07-13       Impact factor: 7.800

Review 4.  Nuclear actions of insulin-like growth factor binding protein-3.

Authors:  Robert C Baxter
Journal:  Gene       Date:  2015-06-12       Impact factor: 3.688

5.  Involvement of the insulin-like growth factor binding proteins in the cancer cell response to DNA damage.

Authors:  Melissa W Y Chua; Mike Z Lin; Janet L Martin; Robert C Baxter
Journal:  J Cell Commun Signal       Date:  2015-01-25       Impact factor: 5.782

6.  IGFBP-3 interacts with NONO and SFPQ in PARP-dependent DNA damage repair in triple-negative breast cancer.

Authors:  Hasanthi C de Silva; Mike Z Lin; Leo Phillips; Janet L Martin; Robert C Baxter
Journal:  Cell Mol Life Sci       Date:  2019-02-06       Impact factor: 9.261

7.  The association between peripheral total IGF-1, IGFBP-3, and IGF-1/IGFBP-3 and functional and cognitive outcomes in the Mayo Clinic Study of Aging.

Authors:  Alexandra M V Wennberg; Clinton E Hagen; Mary M Machulda; John H Hollman; Rosebud O Roberts; David S Knopman; Ronald C Petersen; Michelle M Mielke
Journal:  Neurobiol Aging       Date:  2018-02-19       Impact factor: 4.673

8.  Insulin-like growth factor binding protein-3 (IGFBP-3): Novel ligands mediate unexpected functions.

Authors:  Robert C Baxter
Journal:  J Cell Commun Signal       Date:  2013-08       Impact factor: 5.782

Review 9.  IGF binding proteins in cancer: mechanistic and clinical insights.

Authors:  Robert C Baxter
Journal:  Nat Rev Cancer       Date:  2014-04-10       Impact factor: 60.716

Review 10.  IGF binding proteins (IGFBPs) and regulation of breast cancer biology.

Authors:  Claire M Perks; Jeff M P Holly
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-11-25       Impact factor: 2.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.